Who can benefit from SHINGRIX?
There is a 1 in 4 lifetime risk of developing shingles.5 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.6,7
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Pooled data from two large, phase 3 randomised controlled trials: ZOE-50 (subjects 50 years of age and older) and ZOE-70 (subjects 70 years of age and older). 13,881 patients received SHINGRIX (mTVC).1
4 cases of PHN were reported in the SHINGRIX group. All 4 cases of PHN were in subjects over 70 years of age.1
PHN was defined as HZ-associated pain rated as 3 or higher on a 0-10 scale, occurring or persisting for more than 90 days following the onset of a rash using the Zoster Brief Pain Inventory questionnaire.1,2
REDUCTION OF OTHER SHINGLES-RELATED COMPLICATIONS1,2
The evaluated HZ-related complications were: HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease including stroke, and visceral disease. In the pooled analysis of ZOE-50 and ZOE-70, SHINGRIX significantly reduced these HZ-related complications versus placebo by 93.7% (95% CI: 59.5; 99.9) and 91.6% (95% CI: 43.3; 99.8) in adults 50 years of age or older (1 vs.16 cases) and adults 70 years of age or older (1 vs.12 cases), respectively.1,2
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.